Key facts
- It has raised $210.8M; the latest was Grant ($79.0M) in Apr 2026.
- Notable investors include Page One Ventures, Government of Canada, Radical Ventures, Unreasonable Group, Dimension (United States) — 38 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 38 names
- ·Watchlist + deal alerts for Aspect Biosystems
- ·The full record, as it builds
Funding rounds
No funding rounds for Aspect Biosystems are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Aspect Biosystems
Developer of a tissue-therapeutic platform designed to bioprint implantable tissues that replace, repair, or supplement biological functions for disease treatment. The company offers AI-driven bioprinting technology that creates advances in understanding fundamental biology, disease research, development of novel therapeutics, and regenerative medicine computational design, therapeutic cells, and advanced biomaterials, enabling pharmaceutical partners and healthcare providers to advance regenerative medicine with implantable tissues that target metabolic and endocrine disorders.
- Sector
- Healthcare
- HQ
- Vancouver, Canada
- Founded
- 2013
- Employees
- 130
- Website
- aspectbiosystems.com/
- Ownership
- Privately Held (backing)
Aspect Biosystems doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Aspect Biosystems shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Aspect Biosystems in its N-PORT filings yet. We sweep new filings monthly.